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Abstract
Tissue-specific autoimmune diseases such as type 1 diabetes (T1D) are characterized by T cell-
driven pathology. Administration of autoantigenic peptides provides a strategy to selectively target 
the pathogenic T cell response. Indeed, treatment with β cell peptides effectively prevents T1D in 
NOD mice. However, the efficacy of peptide immunotherapy generally wanes as β cell 
autoimmunity progresses and islet inflammation increases. With the goal of enhancing the efficacy 
of peptide immunotherapy, soluble (s)IAg7-Ig dimers covalently linked to β cell autoantigen-
derived peptides were tested for the capacity to suppress late preclinical T1D. NOD female mice 
with established β cell autoimmunity were vaccinated i.v. with a short course of sIAg7-Ig dimers 
tethered to peptides derived from glutamic acid decarboxylase (GAD)65 (sIAg7-pGAD65). 
Treatment with sIAg7-pGAD65 dimers and the equivalent of only ~7 μg of native peptide 
effectively blocked the progression of insulitis and the development of diabetes. Furthermore, 
suppression of T1D was dependent on β cell-specific IL-10-secreting CD4+ T cells, although the 
frequency of GAD65-specific FoxP3-expressing CD4+ T cells was also increased in sIAg7-
pGAD65 dimer vaccinated NOD mice. These results demonstrate that MHC class II-Ig dimer 
vaccination is a robust approach to suppress ongoing T cell-mediated autoimmunity, and may 
provide a superior strategy of adjuvant-free peptide-based immunotherapy to induce 
immunoregulatory T cells.
Various tissue-specific autoimmune diseases such as type 1 diabetes (T1D)3 are mediated by 
pathogenic T cells (1–3). Considerable effort has been devoted to developing therapeutic 
approaches to target autoreactive T cells, and prevent or suppress tissue-specific 
autoimmunity. Strategies based on administration of immunosuppressant drugs, and Abs 
specific for T cells have been successfully used in experimental models, and in some 
instances the clinic (4–7). However, these approaches fail to discriminate between T cells 
specific for self- and foreign Ags, and compromise the normal function of the immune 
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system to varying degrees. Peptide-based immunotherapies offer an approach to selectively 
target autoreactive T cells, leaving the remainder of the immune system intact (8). 
Approaches of peptide immunotherapy that induce IL-4- or IL-10-secreting adaptive 
immunoregulatory CD4+ T (aTreg) cells have proven to be effective for autoimmune 
diseases in which multiple autoantigens are targeted by T cells (9–11). Once established 
aTreg cells traffic to the relevant tissues and suppress, via cytokine secretion, the 
differentiation or function of pathogenic T effector cells in an Ag-independent manner (12).
Studies in the NOD mouse, a spontaneous model of T1D, demonstrate that administration of 
β cell peptides induces aTreg cells, and suppresses differentiation of type 1 T effector cells 
that mediate destruction of the insulin-producing β cells (9, 10, 13). Peptide immunotherapy 
is effective at early stages of disease progression but efficacy is generally limited at late 
preclinical stages of T1D when the frequency of pathogenic type 1 T effectors is high, and 
the proinflammatory milieu is well established in the β cell containing islets (14, 15). In 
addition to the stage of disease progression at which treatment is initiated, other factors 
influence the efficacy of peptide immunotherapy including dose and route of administration, 
the use of adjuvant, the binding affinity of peptides to MHC molecules, and in vivo peptide 
stability. For instance, peptides are rapidly cleared from the circulation and inefficiently 
presented by APC in vivo, which limits therapeutic efficacy (16–18).
One approach to overcome these limitations has been the engineering of peptide-soluble 
MHC class II-Ig (peptide-sMHCII-Ig) fusion proteins (19–23). These recombinants consist 
of the extra-cellular domains of the MHCII α- and β-chains supported by an Ig scaffold. A 
peptide is tethered to the sMHCII β-chain ensuring that each bivalent fusion molecule 
presents a peptide, which binds T cells directly independent of APC. Studies by Casares et 
al. (24) using a monoclonal TCR transgenic model targeting the neo-β cell autoantigen 
hemagglutinin (HA), provided initial evidence that peptide-sMHCII-Ig vaccination can be 
effective in treating autoimmunity. Administration of sIEd-Ig dimers linked to a HA peptide 
was found to delete HA-specific T effectors and reverse diabetes in treated mice expressing 
HA in β cells. sIEd-Ig dimer vaccination also induced HA-specific aTreg cells (24). 
Nevertheless, whether peptide-sMHCII-Ig vaccination can block autoimmunity mediated by 
pathogenic effector T cells with multiple specificities has yet to be established. Accordingly, 
we tested whether administration of sIAg7-Ig dimers covalently linked to β cell-derived 
peptides could suppress a late preclinical stage of T1D in NOD mice.
Materials and Methods
Mice
NOD/LtJ, NOD.IL-10null, and NOD.CB17.Prkdcscid/J (NOD.scid) mice were maintained 
and bred under specific-pathogen free conditions. Mice were diagnosed as diabetic with 
blood glucose measurements ≥250 mg/dl on three successive days as determined by an 
Autokit Glucose CII assay (WAKO). In our colony NOD female mice 12 wk of age typically 
exhibit elevated blood glucose levels (e.g., ~180–200 mg/dl). All procedures were reviewed 
and approved by the University of North Carolina Institutional Animal Care and Use 
Committee.
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sIAg7-Ig dimer expression, purification, and vaccination
sIAg7-Ig dimers were engineered as previously described (25, 26). Briefly, IAg7 α- and β-
chain extracellular domains were attached to fos and jun leucine zippers, respectively. The 
IAd α-chain was further modified with a murine IgG2a Fc domain to establish a divalent 
structure. Leucine residues at positions 234 and 235 in the IgG2a hinge region were 
substituted with alanines to prevent binding to FcγRI and FcγRII and activation of APC (27, 
28). Peptide epitopes were covalently linked to the N terminus of the IAg7 β-chain by a 
flexible thrombin-GGGGS linker. cDNAs encoding the sIAg7-Ig chains were subcloned into 
the pMT-Bip vector (Invitrogen) and transgene expression driven by a metallothionein-
inducible promoter. Expression vectors were cotransfected via calcium phosphate into 
Drosophila S2 cells with pHygro, and transfectants selected in hygromycin-containing 
Schneider’s medium. sIAg7-Ig dimer protein expression was induced by 500 μM CuSO4 for 
7–10 days and purified by affinity chromatography on a protein A column (GE Bioscience).
Twelve-wk-old NOD female mice were i.v. immunized with 50 μg of sIAg7-Ig dimers 
prepared in 200 μl of PBS on three consecutive days. Three weeks later, a second course of 
three injections of sIAg7-Ig dimer was administered. In some experiments, 12-wk-old NOD 
female mice received three i.p. injections of 200 μg of peptide emulsified in 0.1 ml of IFA 
over a 3-wk period. Mixtures of peptides were also prepared in 0.1 ml of IFA.
FACS analysis
sIAg7-Ig dimers were multimerized using Alexa Fluor 647-coupled protein A (Molecular 
Probes and Invitrogen) for FACS. Cells were incubated with sIAg7-Ig multimers at room 
temperature for 1 h, followed by anti-CD3 (FITC), and CD4 (PacBlue) Abs (eBioscience) 
staining on ice for 30 min. Cells were then fixed, permeabilized, and intracellularly stained 
with anti-FoxP3 (PE) or anti–IL-10 (FITC) Abs (eBioscience).
In some experiments single cell suspensions were cultured with plate-bound anti-CD3 (2 
μg/ml) and soluble anti-CD28 (2 μg/ml) Abs in the presence of recombinant murine IL-2 (10 
ng/ml) for 2 days, and then stimulated with PMA (5 ng/ml) and ionomycin (500 ng/ml) in 
the presence of brefeldin A (10 μg/ml) for 5 h. Cells were stained with sIAg7-Ig multimers at 
room temperature for 1 h, followed by anti-CD3 (PeCy7), anti-CD4 (PacBlue), and anti-
TGF-β (PerCp) Abs on ice for 30 min, and then fixed, permeabilized, and intracellularly 
stained with anti-IL-10 (FITC) and anti-FoxP3 (PE) Abs (eBioscience). Data were acquired 
on a Cyan flow cytometer (DakoCytomation) and analyzed using Summit software 
(DakoCytomation).
Islet isolation
Pancreas samples were perfused with 0.2 mg/ml Liberase (Roche) and digested for 30 min at 
37°C. Islets were purified via Ficoll gradient, hand-picked and counted. For FACS analyses 
of islet infiltrating T cells, isolated islets were dissociated into a single cell suspension using 
enzyme-free cell dissociation solution (Sigma-Aldrich). Lymphocytes infiltrating the islets 
were collected and cellular debris removed by 70-μm nylon filters.
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ELISPOT was conducted as described (29). Briefly, splenocytes (5 × 105/well) or cells from 
the pancreatic lymph nodes (PLN; 2 × 105/well) were resuspended in HL-1 medium 
(BioWhittaker) and cultured in 96-well ELISPOT plates (Millipore) coated with anti-IFN-γ, 
anti-IL-4, or anti-IL-10 Abs (BD Pharmingen) for 48 h at 37°C. Peptides were added at a 
final concentration of 20 μg/ml. Plates were washed, incubated with the appropriate 
biotinylated anti-mouse cytokine Abs and streptavidin-HRP (BD Pharmingen), and spot 
forming units developed with 100 mM sodium acetate buffer containing 0.3 mg/ml 3-
amino-9-ethylcarbazole (Sigma-Aldrich) and 0.015% hydrogen peroxide. An ImmunoSpot 
plate reader (Cellular Technology) was used to count spot forming unit per well. For ELISA, 
cells were cultured in 96-well microtiter plates, stimulated with peptide as described, and 
culture supernatant was harvested after 48 h. TGF-β was measured via ELISA per the 
manufacturer’s instructions (R&D Systems).
T cell adoptive transfers and histopathology
Splenocytes prepared from diabetic NOD donors (5 × 106) were injected i.p. into 5- to 8-wk-
old NOD.scid mice either: 1) alone, 2) with splenocytes (5 × 106), or 3) CD4+ T cells (5 × 
105) purified by negative selection from sIAg7-Ig dimer treated NOD female mice. In some 
experiments NOD.scid recipients were injected twice weekly with 300 μg of anti-TGF-β Ab 
(1D11.16.8) over a period of 4 wk. In our hands this protocol effectively neutralizes TGF-β 
in vivo. Splenocytes (5 × 106) from diabetes-free sIAg7-Ig dimer treated NOD female mice 
alone were also i.p. injected into NOD.scid mice. Pancreases were harvested, and fixed with 
10% formalin. Serial cross-sections separated by 150 μm were cut and stained with H&E.
Statistical analyses
Statistical analyses were performed using GraphPad Prism software. Incidence of diabetes 
was compared by Kaplan-Meier log-rank test. One-way ANOVA test, χ-square test, and 
Student’s t test were used. Findings were considered significant with values for p ≤ 0.05.
Results
sIAg7-GADp217 or sIAg7-GADp290 dimers suppress ongoing β cell autoimmunity and 
prevent diabetes in NOD female mice
Previous work by our group (9) and a more recent analysis (Fig. 1A) demonstrated that 
coadministration of glutamic acid decarboxylase (GAD)65-specific peptides spanning amino 
acid residues 217 to 236 (GADp217) and residues 290 to 309 (GADp290) prepared in IFA 
suppressed β cell autoimmunity in NOD female mice at a late preclinical stage of T1D and 
prevented diabetes. Lack of diabetes in vaccinated NOD mice correlated with an increased 
frequency of GADp217- and GADp290-specific T cells secreting IL-4 but not IL-10 (Fig. 
1B). Nevertheless, protection was induced only after multiple injections with high doses 
(e.g., 200 μg each injection) of the respective peptides in IFA. Furthermore, administration 
of either GADp217 or GADp290 alone failed to prevent diabetes (Fig. 1B) (9). With this in 
mind, we investigated whether sIAg7-Ig dimer vaccination is a more efficient strategy of 
peptide-based immunotherapy.
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sIAg7-Ig dimers were tested which contained covalently linked GADp217 and GADp290, 
and the non-self hen egg lysozyme (HEL) epitope 12–26. T cell binding and stimulation by 
the respective sIAg7-Ig dimers were verified (data not shown). Twelve-wk-old NOD female 
mice, representing a late preclinical stage of T1D, received three i.v. injections of 50 μg of 
sIAg7-Ig in PBS over 3 days, followed by another three injections 3 wk later, and diabetes 
monitored up to 35 wk of age. Each 50-μg injection of sIAg7-Ig was equivalent to 1.1 μg of 
native peptide. No significant difference in the time of onset or frequency of diabetes was 
detected in NOD mice left untreated or receiving sIAg7-HEL (Fig. 2A). In contrast, the 
majority of NOD mice treated with sIAg7-GADp217 (8/10; p = 0.0017 vs untreated mice χ-
square) or sIAg7-GADp290 (9/10; p = 0.0003 vs untreated mice χ-square) dimers remained 
diabetes-free (Fig. 2A). These results demonstrate that administration of sIAg7-GADp217 or 
sIAg7-GADp290, but not sIAg7-HEL, efficiently prevents diabetes at a late preclinical stage 
of T1D.
Nondiabetic 35-wk-old NOD female mice treated with sIAg7-GADp217 or sIAg7-GADp290 
were examined for islet infiltration. Histological analysis of pancreas samples showed a 
significantly reduced frequency and severity of insulitis in nondiabetic 35-wk-old NOD 
female mice treated with sIAg7-GADp217 or sIAg7-GADp290 compared with a group of 
untreated, 35-wk-old NOD female mice (Fig. 2B). Interestingly, the frequency and severity 
of insulitis in the 35-wk-old sIAg7-GAD65-treated NOD mice was analogous to that of 
untreated 12-wk-old NOD female mice (Fig. 2B). Therefore sIAg7-Ig dimer treatment 
prevents diabetes by suppressing the progression of islet infiltration in a β cell peptide-
specific manner.
sIAg7-GADp217 and sIAg7-GADp290 vaccination blocks T1D progression by aTreg cell 
induction
Treatment with self-peptide can mediate T cell tolerance by clonal anergy or deletion. 
Alternatively, self-peptide-specific aTreg cells can be induced that traffic to the site of 
inflammation, and suppress the differentiation or activity of pathogenic T effectors. To 
determine whether active immunoregulation was established by sIAg7-Ig dimer treatment, 
adoptive transfer experiments were conducted. Twelve-week-old NOD female mice were 
treated with sIAg7-GADp217 as described, and splenocytes harvested 3 wk after the last 
injection. Splenocytes from sIAg7-GADp217- or sIAg7-HEL treated groups were then mixed 
with splenocytes prepared from diabetic NOD donor mice and i.p. injected into NOD.scid 
recipients. Mice were monitored for diabetes. As expected, transfer of diabetogenic 
splenocytes alone or mixed with splenocytes from sIAg7-HEL treated NOD donors induced 
diabetes in all of the recipients (Fig. 3). In contrast, the onset of diabetes was significantly 
delayed in NOD.scid mice receiving an equal mixture of splenocytes from sIAg7-GADp217 
treated and diabetic animals (p ≤ 0.002) (Fig. 3). Notably, transfer of splenocytes prepared 
from sIAg7-GADp217 treated mice alone failed to induce diabetes in NOD.scid recipients 
(0/6), indicating a lack of pathogenic T effectors (Fig. 3). The lack of diabetogenic activity 
and the suppressive effect of splenocytes suggested that the protection induced by sIAg7-
GADp217 treatment was mediated by active immunoregulation.
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Next, the nature of the T cell response induced by the sIAg7-Ig dimers was studied. NOD 
female mice 12 wk of age were treated as above, and 3 wk after the last injection the 
frequency of IL-4-, IL-10-, and IFN-γ-secreting T cells in response to a panel of β cell 
peptides was measured via ELISPOT in the PLN and spleen. Cultures established from the 
sIAg7-GADp217 and sIAg7-GADp290 treated mice exhibited a significant increase in the 
frequency of p217- and p290-specific IL-10- but not IL-4-secreting T cells, respectively, 
compared with sIAg7-HEL-injected animals (Fig. 4A). In addition, IL-10-secreting T cells 
specific for proinsulin (B24-C36) and insulin B chain (p9-23) were increased in the PLN of 
sIAg7-GADp217 and sIAg7-GADp290 treated groups vs sIAg7-HEL treated mice (Fig. 4A), 
indicating epitope spread among IL-10-secreting aTreg cells. TGF-μ1 was not detected in 
supernatants of peptide-pulsed cultures established from the spleen and PLN of any of the 
treatment and control groups as measured by ELISA (data not shown). In addition, a 
significant increase in the frequency of CD4+ T cells that bind sIAg7-GADp217 multimer 
and expressed intracellular IL-10 was detected in the spleen, PLN, and islets of sIAg7-
GADp217 treated but not sIAg7-HEL treated mice (Fig. 4, B and C). These results 
demonstrate that protection mediated by sIAg7-GADp217 and sIAg7-GADp290 treatment 
corresponds with the induction of IL-10- but not IL-4- or TGF-β1-secreting aTreg cells 
found in the spleen, PLN, and islets.
sIAg7-GADp217 vaccination increases the frequency of GADp217-specific FoxP3-
expressing Treg cells
Because FoxP3-expressing Treg cells play a key role in regulating self-tolerance (30–32), 
whether sIAg7-Ig dimer treatment increased FoxP3-expressing Treg cells was investigated. 
The frequency of “bulk” FoxP3-expressing CD4+CD25+ T cells in the spleen, PLN, 
mesenteric lymph nodes (MLN) and islets and in vitro suppressor function of these Treg 
cells were similar in sIAg7-GADp217 and sIAg7-HEL treated NOD mice (see supplemental 
Fig. 1).4 No sIAg7-GADp217 multimer binding CD4+ T cells that expressed FoxP3 were 
detected in the spleen, PLN, MLN, and islets of sIAg7-HEL treated NOD mice (Fig. 5). 
Conversely, an increased frequency of sIAg7-GADp217 multimer-binding FoxP3-expressing 
CD4+ T cells was detected in the islets, and to a lesser extent the PLN and spleen but not the 
MLN of NOD mice treated with sIAg7-GADp217 (Fig. 5). Furthermore, the majority 
(~90%) of these FoxP3-expressing CD4+ T cells expressed surface TGF-β1 (Fig. 5A), 
whereas none expressed intra-cellular IL-10 (data not shown). These results demonstrate that 
sIAg7-Ig dimer vaccination induces or expands FoxP3-expressing Treg cells in a peptide-
specific manner.
IL-10 is necessary for protection induced by sIAg7-Ig dimer vaccination
Because sIAg7-GADp217 treatment induced IL-10-expressing T cells, the relative 
contribution of these aTreg cells in mediating protection was examined. Twelve-week-old 
female NOD mice lacking IL-10 expression (NOD.IL-10null) or wild-type NOD mice were 
vaccinated with sIAg7-GADp217 as described. Three weeks after the last injection CD4+ T 
cells were purified via negative selection. CD4+ T cells were then mixed with splenocytes 
prepared from diabetic NOD donors, transferred into groups of NOD. scid recipients, and 
4The online version of this article contains supplemental material.
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the onset of diabetes monitored. All of the NOD.scid mice receiving the diabetogenic 
splenocytes only developed diabetes (Fig. 6A). In marked contrast, CD4+ T cells from NOD 
mice treated with sIAg7-GADp217 effectively blocked the transfer of diabetes; 5 of 6 
NOD.scid recipients remained diabetes-free (Fig. 6A). In contrast, the mixture containing 
CD4+ T cells from sIAg7-GADp217 treated NOD.IL-10null mice failed to prevent the 
transfer of diabetes (Fig. 6A). These results demonstrate that IL-10-secreting aTreg cells 
induced by sIAg7-Ig dimer vaccination play a key role in suppressing the function of 
established pathogenic T effectors.
Next, whether IL-10 was required for the induction or expansion of FoxP3-expressing Treg 
cells by sIAg7-Ig dimer vaccination was determined. Wild-type and NOD.IL-10null female 
mice received sIAg7-GADp217 injections as described, and 3 wk after the final injection, 
tissues were harvested and T cells stained with sIAg7-GADp217 multimer ex vivo. As 
demonstrated in Fig. 6B, no significant difference in the frequency of sIAg7-GADp217 
multimer binding CD4+ T cells expressing FoxP3 was detected in the spleen, PLN, MLN, 
and islets of NOD and NOD.IL-10null female mice vaccinated with sIAg7-GADp217. These 
results indicated that induction/expansion of peptide-specific FoxP3-expressing Treg cells 
was independent of endogenous IL-10, and that these immunoregulatory effectors play only 
a limited role in sIAg7-GADp217-induced protection. To confirm the latter, a coadoptive 
transfer experiment was conducted. CD4+ T cells were isolated from the PLN of NOD 
female mice treated at 12 wk of age with sIAg7-GADp217 or sIAg7-HEL dimer, and then 
injected with diabetogenic splenocytes into NOD.scid recipients. One group of recipients 
was treated with a neutralizing anti-TGF-β Ab. As expected, CD4+ T cells from sIAg7-
GADp217 but not sIAg7-HEL dimer treated NOD mice blocked the transfer of diabetes (Fig. 
6C). Notably, administration of anti-TGF-β Ab had no effect on the protection mediated by 
Treg cells induced by sIAg7-GADp217 dimer vaccination (Fig. 6C). Altogether these results 
demonstrate that protection induced by sMHCII-Ig dimer treatment is primarily mediated by 
IL-10-secreting aTreg cells, and that Treg cells expressing TGF-β and FoxP3 have only a 
limited role.
Discussion
Administration of peptide-sMHCII recombinants has been shown to tolerize pathogenic T 
cells in mono-specific models of autoimmunity (24), including collagen induced arthritis 
(22), experimental autoimmune uveitis (33, 34), and experimental autoimmune 
encephalomyelitis (35). In these studies, prevention or suppression of induced autoimmunity 
has been associated with establishing hyporeactivity in the pathogenic peptide-specific T 
effector cells, or eliciting peptide-specific Treg cell reactivity. The current work provides 
evidence that sMHCII-Ig dimer vaccination effectively suppresses a diverse repertoire of 
established autoreactive T effector cells via induction of IL-10-secreting aTreg cells. The 
former is demonstrated by sIAg7-Ig dimer vaccination blocking β cell autoimmunity at a late 
preclinical stage of T1D in NOD mice (Figs. 1 and 2). Based on dose and relative efficacy of 
a given epitope to mediate protection, sIAg7-Ig dimer treatment was found to be more potent 
than administering the corresponding native GAD65 peptides (Fig. 1A) (9). Coinjection of a 
total of 600 μg of each native GADp217 and GADp290 prepared in IFA prevented diabetes 
in 12-wk-old NOD female mice, and when injected individually neither peptide was 
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protective (Fig. 1A) (9). Furthermore, coinjection of up to 600 μg of each soluble GADp217 
and GADp290 (e.g., in the absence of adjuvant) also had no protective effect in 12-wk-old 
NOD female mice (R. Tisch, unpublished results). In contrast, the equivalent of only ~7 μg 
total of native GAD65 peptide was sufficient to block diabetes using the sIAg7-Ig dimers, 
and either sIAg7-GADp217 or sIAg7-GADp290 alone did so equally well (Fig. 2). A single 
round of three injections of sIAg7-GADp217 or sIAg7-GADp290 had only a limited effect 
on the development of diabetes, indicating that the second set of sMHCII-Ig dimer injections 
is required to “boost” the immunoregulatory response (L. Li and R. Tisch, unpublished 
results).
The robust nature of sMHCII-Ig dimer vaccination is likely due to a variety of parameters. In 
vivo induction of aTreg cells is expected to be more efficient following treatment with 
sMHCII-Ig dimers relative to native peptide. For instance, a number of factors influence the 
efficacy of injected native peptide to stimulate aTreg cell induction/expansion including the 
binding affinity of the peptide for the MHCII molecule, the stability of the peptide-MHCII 
complex, and the type and number of APC presenting the peptide. However, these factors 
are negated by the use of sMHCII-Ig dimers because the peptide is covalently linked and the 
dimer complex directly binds T cells. Direct binding of sMHCII-Ig complexes would also be 
expected to enhance clonal anergy/deletion of CD4+ T cells at a sufficient dose (20, 22). 
Under the conditions used in this study, however, sIAg7-Ig-induced clonal anergy/deletion 
appears to have a minimal (if any) role in the tolergenic effect. For instance, significant 
expansion of GADp217-specific CD4+ T cells (~5-fold) was detected in the islets of sIAg7-
GADp217 vs sIAg7-HEL treated NOD mice (Fig. 4B).
Another likely parameter contributing to the potency of sMHCII-Ig dimer vaccination is the 
nature of Treg cells that are induced or expanded. For instance, protection induced in NOD 
mice by coinjection of native GADp217 and GADp290 in IFA correlated with an increased 
frequency of IL-4- but not IL-10-secreting CD4+ T cells (Fig. 1B) (9), which in turn was 
reflected by the inability of the native GAD65 peptides to prevent diabetes in NOD.IL-4null 
mice (9). In contrast, protection induced by sIAg7-GADp217 or sIAg7-GADp290 
vaccination was dependent on IL-10-secreting CD4+ T cells. These results are consistent 
with findings made by Casares et al. (24) demonstrating that sIEd-HA dimer vaccination 
elicits IL-10-secreting aTreg cells in vivo. IL-10-secreting effector cells are a particularly 
potent subset of aTreg cells by regulating the responses of naive and memory T cells, and 
suppressing Th1 cell-mediated pathologies through bystander suppression mediated by local 
release of IL-10 (36–38). IL-10 also inhibits the activation and function of APC such as 
dendritic cells (39 – 41). IL-10-treated dendritic cells gain a “tolergenic” phenotype and 
preferentially promote the development of aTreg cells (40 – 42). These direct and indirect 
effects of IL-10 would be expected to amplify the immunoregulatory response induced by 
sIAg7-Ig dimer vaccination and may explain the abrupt block in the progression of insulitis 
in protected NOD mice (Fig. 2B). Indeed, sIAg7-p217 and sIAg7-GADp290 treatment 
induced not only GAD65-specific IL-10-secreting aTreg cells, but also aTreg-specific for 
other β cell peptides (Fig. 4A). The relative potency of IL-10-secreting aTreg cells may also 
explain why sIAg7-p217 or sIAg7-GADp290 alone suppressed ongoing β cell autoimmunity 
(Fig. 2A), whereas coinjection of native GADp217 and GADp290 in IFA was needed to 
similarly prevent diabetes onset (Fig. 1A). Injection of both native GAD65-derived peptides 
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in IFA likely is required to induce a sufficient frequency of IL-4-secreting CD4+ T cells, 
which is limiting with either peptide alone (Fig. 1B). Interestingly, an increase in GADp217-
specific FoxP3- and TGF-β1-expressing Treg cells was also detected in the PLN and islets 
of sIAg7-GADp217 vaccinated NOD mice (Fig. 5). Although protection mediated by sIAg7-
Ig dimer was dependent on induction of IL-10-secreting aTreg cells, β cell-specific FoxP3-
expressing Treg cells would also be expected to contribute to immunoregulation within the 
PLN and islets. However, the increase in GADp217-specific FoxP3-expressing Treg cells 
(Fig. 6B) was insufficient to suppress diabetogenic T effectors in the absence of IL-10-
secreting aTreg cells (Fig. 6A), and neutralizing TGF-β had no effect on the regulatory 
function of CD4+ T cells from sIAg7-p217 vaccinated NOD mice (Fig. 6C).
Based on our findings and the findings of other studies (23, 24), properties intrinsic to 
sMHCII-Ig dimers favor differentiation of naive T precursors toward IL-10-secreting aTreg 
cells. sMHCII-Ig dimers may also preferentially expand established IL-10-expressing aTreg 
cells. For instance Liu and colleagues (43) have detected GAD65-specific IL-10-expressing 
CD4+ T cells in the spleens of unmanipulated 8-wk-old NOD mice. However, the identity of 
the peptide bound by sMHCII-Ig dimer also appears to be a key factor determining the 
efficacy of a given recombinant. For instance, the Bluestone group (23) reported that 
vaccinating young NOD mice with a sIAg7-Ig dimer complexed with a mimetic peptide 
recognized by TCR transgenic BDC2.5 CD4+ T cells (sIAg7-p31) failed to induce aTreg 
cells that prevent diabetes in an adoptive transfer model. Similarly, we found that 12-wk-old 
NOD female mice injected with sIAg7-Ig dimer containing a different BDC2.5 mimetic 
peptide continued to develop diabetes (L. Li and R. Tisch, unpublished results). 
Nevertheless, preliminary findings demonstrate that vaccination with sIAg7-Ig dimers 
complexed with other β cell-derived autoantigens such as proinsulin, induce IL-10-secreting 
aTreg cells and block β cell autoimmunity in 12-wk-old NOD female mice (R. Tisch, 
unpublished results). Investigation of the biochemical and transcriptional signaling events 
transduced in CD4+ T cells will provide important insight into the events that regulate aTreg 
differentiation by sIAg7-Ig dimers. It is noteworthy that induction of aTreg cells is also 
achieved by administration of soluble peptide-linked single chain recombinants consisting of 
the α1 and β1 domains of MHCII (34, 35, 44). These recombinant TCR ligands directly 
bind to TCR independent of CD4, and have been found to also induce T cell hyporeactivity. 
Similar to our findings, a recent report showed that vaccination with recombinant TCR 
ligands linked to peptides derived from proteolipid protein reversed in mice experimental 
autoimmune encephalomyelitis induced by a whole spinal cord homogenate via induction of 
proteolipid protein-specific IL-10- (and IL-13-) secreting aTreg cells (44). This finding 
further argues that soluble peptide-MHCII vaccination may in general prove to be a highly 
effective approach of peptide immunotherapy to preferentially promote aTreg cell reactivity 
and suppress ongoing autoimmunity.
In summary, our findings indicate that peptide-sMHCII-Ig dimer treatment is a robust 
approach to suppress late preclinical β cell autoimmunity via induction of immunoregulatory 
T effector cells. This work also provides rationale for using sMHCII-Ig dimer vaccination as 
a mode of adjuvant-free peptide immunotherapy in the clinic. For instance, HLA-DR4 or 
HLA-DQ8 recombinants covalently linked to known β cell-derived peptides restricted to the 
corresponding HLA molecules can be used to induce IL-10-secreting aTreg cells. The 
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apparent intrinsic property of sMHCII-Ig dimers to induce IL-10-secreting aTreg cells is 
particularly relevant in view of work by Peakman and colleagues (45). This group 
demonstrated an increased frequency of HLA-DR4-restricted β cell peptide-specific CD4+ T 
cells secreting IL-10 in HLA-matched healthy control vs diabetic individuals. A role for 
IL-10-secreting Treg cells has also been implicated in other tissue specific autoimmune 
diseases such as multiple sclerosis (46). The relatively low dose of total native peptide 
required to induce protection also has important safety implications in view of murine and 
clinical studies reporting anaphylaxis following administration of high doses of soluble 
peptide (47–49). Currently, efforts are ongoing in the laboratory to assess the properties of 
such HLA sMHCII-Ig dimers.
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Diabetes is prevented in NOD mice at a late preclinical stage of T1D with multiple and high 
doses of “native” GAD65 peptides in adjuvant. A, Groups of n = 8 NOD female mice 12 wk 
of age received a total of three i.p. injections of 200 μg of peptide in IFA over a 20-day 
period. Diabetes was monitored. *, p < 10−3 by Kaplan-Meier log-rank test for NOD mice 
coinjected with GADp217 and GADp290 vs NOD mice receiving only GADp217 or 
GADp290 or left untreated (UnTx). B, PLN were harvested from individual NOD female 
mice (n = 4) 3 wk after the last injection of peptide in IFA as in A, and the frequency of IFN-
γ-, IL-4-, and IL-10-secreting T cells in response to 20 μg/ml peptide was measured by 
ELISPOT. Error bar represents mean ± SEM. *, p < 10−3, NOD mice treated with GADp217 
or GADp290 alone vs HEL-treated or untreated animals. **, p < 10−3 by Student’s t test, for 
NOD mice coinjected with GADp217 and GADp290 vs NOD mice treated with GADp217 
or GADp290 only.
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sIAg7-GADp217 and sIAg7-GADp290 treatment prevents diabetes and blocks the 
progression of insulitis at a late preclinical stage of T1D. A, Twelve-wk-old NOD female 
mice were treated with sIAg7-GADp217 (n = 10), sIAg7-GADp290 (n = 10), sIAg7-HEL (n 
= 8), or left untreated (UnTx, n = 10), and diabetes was monitored. *, p ≤ 0.0015 by Kaplan-
Meier log-rank test, for sIAg7-GADp217 vs sIAg7-HEL treated or untreated mice and †, p ≤ 
0.0003, for sIAg7-GADp290 vs sIAg7-HEL treated or untreated mice. B, Insulitis in the 
pancreases of nondiabetic NOD female mice treated with sIAg7-GADp217 (n = 5) and 
sIAg7-GADp290 (n = 6) was evaluated at 35 wk by histological analysis. In addition, 
insulitis in the pancreases of untreated (UnTx) nondiabetic NOD female mice 12 wk (n = 4) 
and 35 wk (n = 5) of age were compared; and diabetic NOD female mice treated with sIAg7-
HEL (n = 4). A minimum of 30 islets was examined for each mouse. p < 10−3 by one-way 
ANOVA test for frequency and severity of insulitis in sIAg7-GADp217 or sIAg7-GADp290 
treated NOD mice vs 35-wk-old untreated NOD female mice.
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sIAg7-GADp217 vaccination induces active immunoregulation. NOD.scid mice received 5 × 
106 splenocytes from diabetic (n = 11) or nondiabetic sIAg7-GADp217 treated (n = 6) NOD 
female mice alone, or a mixture of an equal number of splenocytes (5 × 106) from diabetic 
NOD plus sIAg7-GADp217 (n = 7) or sIAg7-HEL (n = 5) dimer treated NOD donors, and 
diabetes was monitored. *, p = 0.0005, by Kaplan-Meier log-rank test, for diabetogenic 
splenocytes alone vs sIAg7-GADp217 splenocytes alone and †, p ≤ 0.0015, for diabetogenic 
splenocytes alone or a mixture of diabetogenic plus sIAg7-HEL splenocytes vs a mixture of 
diabetogenic plus sIAg7-GADp217 splenocytes.
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sIAg7-GADp217 and sIAg7-GADp290 vaccination induces IL-10-secreting aTreg cells. 
Groups of n = 5 12-wk-old NOD female mice were treated with sIAg7-Ig and 3 wk after the 
second course of injections T cell reactivity assessed. A, Spleen and PLN suspensions were 
examined via ELISPOT, and the frequency of T cells secreting IFN-γ, IL-4, and IL-10 
determined in response to 20 μg/ml peptide. For a given peptide used for in vitro stimulation, 
comparisons were made with cultures established from sIAg7-HEL dimer treated mice. *, p 
= 0.002; †, p = 0.005; ‡, p = 0.01; **, p = 0.0003; ††, p = 0.002; ‡‡, p = 0.005; and §, p = 
0.005 by Student’s t test. Error bar represents mean ± SEM. B, Representative FACS data of 
the frequency of sIAg7-GADp217 multimer-staining CD4+ T cells expressing intracellular 
IL-10 cultured from the islets following anti-CD3 and anti-CD28 Ab stimulation of sIAg7-
GADp217 and sIAg7-HEL dimer treated (Tx) mice. C, Frequency ± SD of sIAg7-GADp217 
multimer-staining CD4+ T cells expressing intra-cellular IL-10 cultured from the spleen, 
PLN, MLN, and islets following anti-CD3 and anti-CD28 Ab stimulation of n = 5 individual 
NOD mice treated with sIAg7-GADp217 or sIAg7-HEL dimers. For a given tissue, 
comparisons were made between sIAg7-GADp217 vs sIAg7-HEL dimer treated mice. *, p = 
0.048, spleen; †, p = 0.003, PLN; ‡, p = 0.01, MLN; and §, p = 0.005 by Student’s t Test. p = 
0.02 by one-way ANOVA test, for frequency of sIAg7-GADp217 multimer-staining IL-10-
expressing CD4+ T cells in sIAg7-GADp217 vs sIAg7-HEL dimer treated NOD mice.
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An increased frequency of GADp217-specific FoxP3-expressing Treg cells is detected in 
sIAg7-GADp217 vaccinated NOD mice. A, Representative FACS data of sIAg7-GADp217 
multimer-binding CD4+ T cells ex vivo expressing FoxP3 and surface TGF-β1 from the 
islets of sIAg7-GADp217 and sIAg7-HEL-treated (Tx) NOD female mice. B, Frequency ± 
SD of sIAg7-GADp217 multimer-staining CD4+ T cells ex vivo expressing FoxP3 in the 
spleen, PLN, MLN, and islets of n = 5 individual NOD female mice treated with sIAg7-
GADp217 and sIAg7-HEL. *, p ≤ 0.004 by Student’s t test, for sIAg7-GADp217 vs sIAg7-
HEL dimer treated animals for a given tissue. p < 10−3 by one-way ANOVA test for sIAg7-
GADp217 vs sIAg7-HEL treated NOD mice.
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Protection mediated by sIAg7-GADp217 treatment is IL-10-dependent. A, Groups of 
NOD.scid mice (n = 4) received diabetogenic splenocytes alone or a mixture of purified 
splenic CD4+ T cells isolated from NOD (n = 6) or NOD.IL-10null (n = 5) female mice 
treated with sIAg7-GADp217, and diabetes was monitored. *, p = 0.001, by Kaplan-Meier 
log-rank test for CD4+ T cells from sIAg7-GADp217 treated (Tx) NOD vs NOD.IL10null 
mice or diabetogenic splenocytes alone. B, Frequency ± SD of sIAg7-GADp217 multimer-
staining CD4+ T cells ex vivo expressing FoxP3 in the spleen, PLN, MLN, and islets of n = 
5 individual NOD (IL-10wt) or NOD.IL-10null (IL-10null) female mice treated with sIAg7-
GADp217 or sIAg7-HEL. C, CD4+ T cells (5 × 106) isolated from the PLN of NOD female 
mice vaccinated at 12 wk of age with sIAg7-GADp217 or sIAg7-HEL were mixed with 
Li et al. Page 18













splenocytes from diabetic NOD donors (5 × 106) and transferred into groups of n = 5 
NOD.scid mice. One group of NOD.scid recipients of CD4+ T cells isolated from sIAg7-
GADp217 vaccinated animals also received a TGF-β-neutralizing Ab. †, p = 0.0002, by 
Kaplan-Meier log-rank test, for recipients of CD4+ T cells from sIAg7-HEL vaccinated mice 
vs recipients of CD4+ T cells from sIAg7-GADp217 vaccinated mice with or without anti-
TGF-β Ab.
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